Literature DB >> 18980207

Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma.

H Ohtani1, Z Jin, S Takegawa, T Nakayama, O Yoshie.   

Abstract

The neoplastic environment is generally regarded as an immunosuppressive milieu. However, a group of cancers are characterized by the abundance of tumour-infiltrating lymphocytes (TILs). Here we examined the possible roles of chemokines in the formation of lymphoid stroma in lymphocyte-rich gastric carcinomas (GCs), including EBV(+) cases and conventional GCs. Regardless of EBV positivity, TILs in lymphocyte-rich GCs predominantly expressed CXCR3, while its ligand CXCL9 was abundantly expressed by stromal cells and a portion of cancer cells. CXCL9(+) stromal cells were judged to include dendritic cells, because they partly co-expressed fascin, DC-sign, CD83, DC-lamp or HLA-DR. T cells in close contact with CXCL9(+) cells showed frequent labelling of Ki-67 (approximately 10%), suggesting the immunostimulatory activity of CXCL9(+) stromal cells. The T-cell zone of the regional lymph nodes of lymphocyte-rich GCs also abounded with CXCR3(+) T cells and CXCL9(+) stromal cells. This indicated a close similarity between cancer stroma and regional lymph nodes of lymphocyte-rich GCs. Quantitative RT-PCR also confirmed the strong expression of CXCR3, CXCL9 and IFNgamma in lymphocyte-rich GCs. In contrast, conventional GCs contained less abundant CXCR3(+) T cells and few CXCL9(+) stromal cells. Collectively, the CXCL9-CXCR3 axis plays a pivotal role in the formation of lymphoid stroma in lymphocyte-rich GCs. Given similar findings in the regional lymph nodes, the lymphoid stroma of lymphocyte-rich GCs may represent a tertiary lymphoid tissue with predominantly Th1-shifted immune responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18980207     DOI: 10.1002/path.2448

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  46 in total

1.  NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells.

Authors:  Ravikumar Muthuswamy; Erik Berk; Beth Fallert Junecko; Herbert J Zeh; Amer H Zureikat; Daniel Normolle; The Minh Luong; Todd A Reinhart; David L Bartlett; Pawel Kalinski
Journal:  Cancer Res       Date:  2012-05-16       Impact factor: 12.701

2.  A digest on the role of the tumor microenvironment in gastrointestinal cancers.

Authors:  Martin Augsten; Christina Hägglöf; Cristina Peña; Arne Ostman
Journal:  Cancer Microenviron       Date:  2010-03-07

3.  Morphometric analysis of the balance between CXCR3+ T cells and FOXP3+ regulatory T cells in lymphocyte-rich and conventional gastric cancers.

Authors:  Haruo Ohtani; Osamu Yoshie
Journal:  Virchows Arch       Date:  2010-04-27       Impact factor: 4.064

4.  Inflammation in gastric adenocarcinoma of the cardia: how do EBV infection, Her2 amplification and cancer progression influence tumor-infiltrating lymphocytes?

Authors:  Matthias Haas; Maike Büttner; Tilman T Rau; Rainer Fietkau; Gerhard G Grabenbauer; Luitpold V Distel
Journal:  Virchows Arch       Date:  2011-02-26       Impact factor: 4.064

Review 5.  Chemokines in health and disease.

Authors:  Dayanidhi Raman; Tammy Sobolik-Delmaire; Ann Richmond
Journal:  Exp Cell Res       Date:  2011-01-09       Impact factor: 3.905

Review 6.  Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.

Authors:  Pawel Kalinski; Hideho Okada
Journal:  Semin Immunol       Date:  2010-04-20       Impact factor: 11.130

Review 7.  CXC chemokines and chemokine receptors in gastric cancer: from basic findings towards therapeutic targeting.

Authors:  Hyo Jin Lee; Ik-Chan Song; Hwan-Jung Yun; Deog-Yeon Jo; Samyong Kim
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 8.  Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4.

Authors:  Pawel Kalinski
Journal:  Curr Opin Investig Drugs       Date:  2009-06

Review 9.  Dendritic cell-based therapeutic cancer vaccines: what we have and what we need.

Authors:  Pawel Kalinski; Julie Urban; Rahul Narang; Erik Berk; Ewa Wieckowski; Ravikumar Muthuswamy
Journal:  Future Oncol       Date:  2009-04       Impact factor: 3.404

Review 10.  Regulation of chemokine expression in the tumor microenvironment.

Authors:  Anton V Gorbachev; Robert L Fairchild
Journal:  Crit Rev Immunol       Date:  2014       Impact factor: 2.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.